AcuraStem harnesses human, patient-specific in vitro cell models and assays to develop cures and improve diagnoses in disorders of the CNS.
AcuraStem has raised $7.5M in total funding. The most recent round was Grant. The last funding was announced in April 2026.
AcuraStem's investors include U.S. Department of War, National Institutes of Health, California Institute for Regenerative Medicine, Viva Biotech, Keiretsu Forum.
AcuraStem is headquartered in Pasadena, United States.
AcuraStem harnesses human, patient-specific in vitro cell models and assays to develop cures and improve diagnoses in disorders of the CNS.
AcuraStem is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AcuraStem — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/acurastem. Accessed November 14, 2026.
VCBacked. (2026). AcuraStem — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/acurastem
{{cite web |title=AcuraStem — Funding & Investors |url=https://www.vcbacked.co/company/acurastem |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AcuraStem? Request a listing update